Merus NV Quote - MRUS

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

53.94

Bid

52.55

Ask

56.97

Volume

621,705

53.50 Day's Range 55.43

0.00 52 Week Range 0.00

Market Cap

Previous Close

54.24

Open

54.05

Last Trade

Last Trade Time

16:31:49

Financial Volume

US$ 33,702,510

VWAP

54.2098

Average Volume (3m)

Shares Outstanding

57,878,284

Dividend Yield

PE Ratio

Earnings Per Share (EPS)

Revenue

Net Profit

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector

Gen Med & Surgical Hospitals

Industry

Gen Med & Surgical Hospitals

Website

www.merus.nl

Headquarters

Utrecht, Utrecht, Nld

Founded

1970

Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was US$54.24. Over the last year, Merus NV shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Merus NV currently has 57,878,284 shares outstanding.

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GRCGold Springs Resource Corp	$ 0.09 (20.00%)	255.2k
SFDNXT Energy Solutions Inc	$ 0.16 (18.52%)	118k
SAMStarcore International Mines Ltd	$ 0.14 (16.67%)	525
DSVDiscovery Silver Corp	$ 1.03 (13.19%)	913.48k
PYRPyroGenesis Canada Inc	$ 0.69 (13.11%)	191.75k
CFXCanfor Pulp Products Inc	$ 1.04 (-25.71%)	141.77k
AEZSAeterna Zentaris Inc	$ 6.04 (-24.50%)	14.45k
LPENLoop Energy Inc	$ 0.025 (-16.67%)	15.04k
ETEvertz Technologies Ltd	$ 13.30 (-13.30%)	120.44k
AABAberdeen International Inc	$ 0.035 (-12.50%)	1.61M
CNQCanadian Natural Resources Ltd	$ 47.87 (1.36%)	29.03M
TRPTC Energy Corporation	$ 52.25 (-0.08%)	14.09M
SUSuncor Energy Inc	$ 50.82 (0.08%)	8.95M
MFCManulife Financial Corporation	$ 35.23 (0.46%)	7.75M
POWPower Corp of Canada	$ 37.57 (-0.71%)	6.65M